Samsung Medison completed a major manufacturing expansion in Hongcheon to increase production of premium ultrasound scanners. The 50 billion won investment adds 14548 square meters of floor space to double total equipment output by 2030. The expansion reinforces supply channels to major hospitals worldwide as the company targets a top 3 position in the global imaging sector.
Samsung Medison invested 50 billion won into the site, marking its largest capital project since joining Samsung Electronics in 2011. The Hongcheon plant builds flagship diagnostic systems including the R20 and HERA Z20. This facility manages the entire production sequence from circuit board fabrication and structural assembly to high temperature reliability tests. The plant generates over 90% of company revenues through exports to 110 countries, operating in coordination with the Gumi facility which raised probe component output by 17%.
The manufacturing floor runs on Samsung b.IoT software and automated building energy management systems. Variable speed inverter systems lower reheat energy consumption by 33.6% and cut climate control power usage by up to 52%. Automated lines track inventory from initial intake to packaging, running total inspection protocols across every build stage to prevent component defects.
Company sales rose 16.2% over the previous annual cycle compared to broader market growth of 3.7%, with internal projections tracking at 3 times the general market average of 4%. Premium scanners currently go to major medical providers including the Mayo Clinic, the Cleveland Clinic, the Karolinska University Hospital, and the United States Department of Defense. Samsung Medison is also expanding into point of care diagnostics with the EVO Q10 laptop and EVO X10 tablet scanners.
Product development teams are collaborating with Samsung Medical Center on dedicated cardiology solutions. The company is also working with cancer therapy developer HistoSonics to stream live R20 imaging feeds directly into the Edison surgical platform for guided treatments.
Samsung Medison CEO Yoo Kyu tae stated that the factory expansion directly addresses growing hospital demand:
This plant expansion serves as a strategic investment to meet growing global demand and expand our operational footprint. By pairing automated manufacturing with internal component production, we intend to provide medical professionals worldwide with zero defect equipment so they can focus on patient care.
